🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06607081
Starting soon Not applicable

Preoperative Risk Evaluation and Per ERAS Intervention in the Chinese Elderly Patients Underwent Spinal Fusion Surgery

NCT06607081 · tracked via the Priya Life Science China tracker
Sponsor
Xijing Hospital
Phase
Not applicable
Started
2024-10-15
Last updated
2024-09-23

Condition(s) studied

Degenerative Spinal DiseaseElderly PatientsSpinal Fusion Acquired

Investigational drug(s) / intervention(s)

Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention

Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention: The operative risk factors are multidisciplinary evaluated and the corresponded multimodal measures are used to optimize the whole condition of the elderly patient undergo spinal fusion surgery for his/her safty, early and fully recovery.

Study summary

This study aims to evaluate the value of preoperative risk factor evaulation combined with perioperative ERAS measures in improving the clinical prognosis of elderly patients undergo the spinal fusion.

Eligibility

Sex
ALL
Min age
75 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * 1.Age ≥75 years old; * 2.Have degenerative spinal diseases, including cervical, thoracic and lumbar spine diseases; * 3.With severe neurological symptoms fail to conservative treatment and have to undergo the spinal fusion surgery; * 4.No serious cognitive impairment (MoCA score ≥8); * 5.No surgical contraindications; * 6.Anesthesia assessment patients can safely undergo surgery; * 7.Patients who voluntarily participate in and sign informed consent, can independently complete effective questionnaires, and are willing to follow up according to clinical requirements. Exclusion Criteria: * 1.Patients who could not cooperate with doctors to complete preoperative evaluation and postoperative follow-up; * 2.Patients requiring spinal intervention due to spinal infection, fracture or metastatic disease; * 3.Patients with cerebrovascular accidents in the last 30 days; * 4.Patients with hepatic encephalopathy or acute active hepatitis; * 5.Patients with severe renal insufficiency with creatinine\>2.5mg/dL or undergoing hemodialysis; * 6.Patients with severe lung and cardiovascular diseases, coagulation disorders, and anesthesia contraindications; * 7.Patients with poorly controlled diabetes (HBAlc\>8.0%); * 8.Patients who are participating in clinical trials of other drugs or medical devices; * 9.Patients requiring emergency surgery; * 10.Patients who are considered by the investigator to be unable to participate in this clinical trial due to other circumstances.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Xijing Hospital Xi'an Shaanxi
Xijing Hospital Xi'an Shaanxi

More Xijing Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06607081 on ClinicalTrials.gov ↗ ← All trials in China